Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

Paul J. Hengeveld; Y. Emre Ertem; Julie M. N. Dubois; Clemens H. M. Mellink; Anne-Marie van der Kevie-Kersemaekers; Ludo M. Evers; Kim Heezen; P. Martijn Kolijn; Olaf R. F. Mook; M. Mahdi Motazacker; Kazem Nasserinejad; S. Kersting; Peter E. Westerweel; Carsten U. Niemann; Arnon P. Kater; Anton W. Langerak; Mark-David Levin

doi:10.1038/s41375-022-01600-6

Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

Paul J. Hengeveld
, Y. Emre Ertem
, Julie M. N. Dubois
, Clemens H. M. Mellink
, Anne-Marie van der Kevie-Kersemaekers
, Ludo M. Evers
, Kim Heezen
, P. Martijn Kolijn
, Olaf R. F. Mook
, M. Mahdi Motazacker
, Kazem Nasserinejad
, S. Kersting
, Peter E. Westerweel
, Carsten U. Niemann
, Arnon P. Kater
, Anton W. Langerak
, Mark-David Levin^*

^*Corresponding author for this work

Erasmus MC
Albert Schweitzer Ziekenhuis
Amsterdam UMC - University of Amsterdam
Erasmus University Rotterdam
Haga Teaching Hospital
University of Copenhagen
Albert Schweitzer Hospital, Dordrecht.
Amsterdam University Medical Centers
Erasmus MC Cancer Institute
Haga Ziekenhuis

Research output: Contribution to journal › Article › Academic › peer-review

39 Downloads (Pure)

Original language	English
Pages (from-to)	1935-1938
Number of pages	4
Journal	Leukemia
Volume	36
Issue number	7
Early online date	2022
DOIs	https://doi.org/10.1038/s41375-022-01600-6
Publication status	Published - 1 Jul 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41375-022-01600-6

Clinicobiological-characteristics-and-treatment-efficacy-of-novel-agents-in-chronic-lymphocytic-leukemia-with-iglv3-21r1.pdfFinal published version, 944 KBLicence: Taverne

Cite this

Hengeveld, P. J., Ertem, Y. E., Dubois, J. M. N., Mellink, C. H. M., van der Kevie-Kersemaekers, A.-M., Evers, L. M., Heezen, K., Kolijn, P. M., Mook, O. R. F., Motazacker, M. M., Nasserinejad, K., Kersting, S., Westerweel, P. E., Niemann, C. U., Kater, A. P., Langerak, A. W., & Levin, M.-D. (2022). Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110. Leukemia, 36(7), 1935-1938. https://doi.org/10.1038/s41375-022-01600-6

@article{e4097ef4e97c41d997ecfceb27a53ada,

title = "Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110",

author = "Hengeveld, \{Paul J.\} and Ertem, \{Y. Emre\} and Dubois, \{Julie M. N.\} and Mellink, \{Clemens H. M.\} and \{van der Kevie-Kersemaekers\}, Anne-Marie and Evers, \{Ludo M.\} and Kim Heezen and Kolijn, \{P. Martijn\} and Mook, \{Olaf R. F.\} and Motazacker, \{M. Mahdi\} and Kazem Nasserinejad and S. Kersting and Westerweel, \{Peter E.\} and Niemann, \{Carsten U.\} and Kater, \{Arnon P.\} and Langerak, \{Anton W.\} and Mark-David Levin",

note = "Funding Information: SK has received personal fees from Janssen, AbbVie, Novartis, Gilead, and Celgene; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. CUN received research funding and/or consultancy fees from Abbvie, AstraZeneca, Roche, Janssen, CSL Behring, Takeda, and Octapharma. APK has received personal fees from AbbVie, LAVA, Genmab, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb; and research funding from AbbVie, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb. AWL has received research support via an unrestricted grant from Roche-Genentech and a speaker-fee from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. All other authors declare no competing interests. Funding Information: The HOVON-139/GIVE trial was funded by F Hoffmann-La Roche (ML29995), who had the opportunity to review and comment on this paper. The HOVON-141/VIsion trial was supported by AbbVie and Janssen/Pharmacyclics, who had the opportunity to review and comment on this paper. In addition, the HOVON-141/VIsion trial was funded by the Novo Nordisk Foundation grant NNF160C0019302.",

year = "2022",

month = jul,

day = "1",

doi = "10.1038/s41375-022-01600-6",

language = "English",

volume = "36",

pages = "1935--1938",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "7",

}

Hengeveld, PJ, Ertem, YE, Dubois, JMN, Mellink, CHM , van der Kevie-Kersemaekers, A-M, Evers, LM, Heezen, K, Kolijn, PM, Mook, ORF , Motazacker, MM, Nasserinejad, K, Kersting, S, Westerweel, PE, Niemann, CU, Kater, AP, Langerak, AW & Levin, M-D 2022, 'Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110', Leukemia, vol. 36, no. 7, pp. 1935-1938. https://doi.org/10.1038/s41375-022-01600-6

TY - JOUR

T1 - Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

AU - Hengeveld, Paul J.

AU - Ertem, Y. Emre

AU - Dubois, Julie M. N.

AU - Mellink, Clemens H. M.

AU - van der Kevie-Kersemaekers, Anne-Marie

AU - Evers, Ludo M.

AU - Heezen, Kim

AU - Kolijn, P. Martijn

AU - Mook, Olaf R. F.

AU - Motazacker, M. Mahdi

AU - Nasserinejad, Kazem

AU - Kersting, S.

AU - Westerweel, Peter E.

AU - Niemann, Carsten U.

AU - Kater, Arnon P.

AU - Langerak, Anton W.

AU - Levin, Mark-David

N1 - Funding Information: SK has received personal fees from Janssen, AbbVie, Novartis, Gilead, and Celgene; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. CUN received research funding and/or consultancy fees from Abbvie, AstraZeneca, Roche, Janssen, CSL Behring, Takeda, and Octapharma. APK has received personal fees from AbbVie, LAVA, Genmab, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb; and research funding from AbbVie, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb. AWL has received research support via an unrestricted grant from Roche-Genentech and a speaker-fee from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. All other authors declare no competing interests. Funding Information: The HOVON-139/GIVE trial was funded by F Hoffmann-La Roche (ML29995), who had the opportunity to review and comment on this paper. The HOVON-141/VIsion trial was supported by AbbVie and Janssen/Pharmacyclics, who had the opportunity to review and comment on this paper. In addition, the HOVON-141/VIsion trial was funded by the Novo Nordisk Foundation grant NNF160C0019302.

PY - 2022/7/1

Y1 - 2022/7/1

UR - https://www.scopus.com/pages/publications/85130283203

U2 - 10.1038/s41375-022-01600-6

DO - 10.1038/s41375-022-01600-6

M3 - Article

C2 - 35585140

SN - 0887-6924

VL - 36

SP - 1935

EP - 1938

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

UN SDGs

Access to Document

Other files and links

Cite this